Mountain Valley MD Commencing Husbandry Animal Trials, Appoints Seasoned Physician of Veterinary Medication to Advisory Board

Ad Blocker Detected

Our website is made possible by displaying online advertisements to our visitors. Please consider supporting us by disabling your ad blocker.

TORONTO, March 1, 2021 / CNW / – Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) is pleased to announce that it is commencing animal testing with a third party contract research organization (“CRO”) to validate the superiority of the Company’s injectable solubilized ivermectin technology, Ivectosol ™ 1%, over currently commercially available forms for the treatment of a wide range of animal parasites.

Ivectosol 1% by MVMD is tested in pigs and poultry using advanced needle-less intramuscular injection to demonstrate superior pharmacokinetics in terms of CMAX (maximum serum concentration a drug will reach) and AUC (area under the curve) with targeted drug withdrawal times within 10 days after administration. In addition, the study is expected to demonstrate superior ease of administration while eliminating the typically high retention requirements and injection pain for the animal, while reducing the risk of potentially fatal clostridial infection that is common with conventional penetration of the injection site by large-gauge needles , is drastically reduced.

“This is a very significant project that will develop very quickly and will form the basis for our submissions of new veterinary drug applications to the Food and Drug Administration,” he said Dennis Hancock, President and CEO of Mountain Valley MD. “With our solubilized 1% Ivectosol ™ solution, we will be able to open up new injectable markets for ivermectin such as game and poultry that no longer exist today and enable tens of billions of animal applications worldwide annually.”

The company’s 1% Ivectosol solution uses no harmful organic solvents and has the viscosity of water, enabling novel needleless injector applications. The company believes that the use of needle-free injection systems with a solubilized ivermectin will bring significant benefits to livestock and poultry producers, including increased effectiveness and elimination of disease-transmitting needles and the risk of entering the food supply Ease of administration with reduced labor and safer handling protocols, minimized tissue damage that traditionally negatively impacts yields, and precise dosing that helps eliminate human error.

The continuation of animal testing is part of the company’s plan to use its 1% Ivectosol ™ technology to tap the broad housing and service animal market, which directly affects the cattle, pig and poultry industries with a combined annual consumer market of more than 67 Billions of animals concentrated.

The company is also pleased to announce the launch of Michel Rondeau, Doctor of Veterinary Medicine, as a consultant who will oversee the study and advance global applications for pharmaceutical stance as part of the ongoing commercialization of MVMD technology.

Dr. Rondeau has extensive experience in veterinary research, has worked with numerous pharmaceutical companies in field trials of veterinary drugs and is involved in the co-invention of a world-award winning sprayable vaccination device acquired by Rhone Poulenc. Dr. Rondeau has completed an extensive series of research and development projects for a wide variety of farmed animals, including industrial swine medicine, preventive and medicinal medicine, nutritional and animal health products, and automated feeding systems.

“I am honored to work with Mountain Valley MD in this advisory capacity and drive transformational work that has the potential to transform the animal health industry around the world,” he said Michel Rondeau, Doctor of Veterinary Medicine and Senior Animal Advisor for Mountain Valley MD.

These studies, conducted by Dr. Rondeau, agree with MVMD’s belief that treating potential pandemic diseases in their zoonotic hosts can prevent further outbreaks in humans by eliminating their ability to transmit.

“We believe that these key studies in pigs, and particularly poultry, will highlight the benefits of Ivectosol 1% over all competitive products today,” he said Mike Farber, Director of Life Sciences at Mountain Valley MD. “We anticipate that the antiviral properties of ivermectin will prove extremely valuable in combating outbreaks of influenza viruses such as H5N1 and H5N8 in poultry. The ability to use needle-less applicators to inject Ivectosol 1% will be beneficial for livestock – and the poultry industry will be crucial. “

As reported by Bloomberg ** on February 22, 2021A variant of avian flu that spreads to wild birds and has occasionally spilled on and killed poultry for years, recently caused the first reported human infections in the south Russia. New strains that can infect humans are a cause for concern as they may mutate and become more suitable for the human respiratory tract, causing potentially dangerous epidemics.

MVMD plans to further develop its tests upon completion of the current studies to demonstrate the effectiveness of its proprietary 1% Ivectosol ™ solution in protecting poultry from avian influenza viruses such as H5N8 and H5N1, opening the door to broad herd protection against these rapidly spreading viruses Open viruses.

The company’s previously completed pre-clinical studies with a third-party contract research organization tested the solubilized ivermectin against existing oral and subcutaneous injection solutions using both intramuscular injection and the company’s patented Quicksome ™ -dried liposome technology. Results showed that the company’s patented Quicksol ™ solubilized ivermectin provides superior pharmacokinetic performance with no adverse side effects across any action taken when using up to 1/8 less of the ivermectin drug – a critical component which allows applications to use less ivermectin drug while driving faster viral clearance.

As previously announced, MVMD’s solubility technology applied to the ivermectin drug is the only form in the world that uses only excipients currently approved by the US Food and Drug Administration (FDA). This makes MVMD a leading candidate for injections and sublingual applications in humans, as well as significantly broader housing and companion animal treatments due to its low viscosity.

References / sources
* Global Animal Statistics and Charts: 2020 update

** The bird flu virus that infected humans in Russia

Mountain Valley MD is building a world-class organization for biotech and life science companies focused on implementing its patented Quicksome ™ oral drug formulation and delivery technology and Quicksol ™ macrocyclic lactones solubility technology to innovate industry-leading products that are used worldwide to be sought.

MVMD’s proposal to deliver Quicksome ™ formulations with rapid onset, high bioavailability, low variability and precise dosing is key to the company’s success in all major health and wellness categories. In line with its vision of helping people live their best lives, MVMD is leveraging its Quicksome ™ and Quicksol ™ technologies in its pioneering work in advanced vaccine and drug delivery, as well as in the development of pain management and weight loss products , Energy, focus, sleep, fear and more.

The company’s patented Quicksome ™ drying technology uses advanced liposomes and other stabilizing molecules to encapsulate and formulate active ingredients in highly efficient product formats that are consumed orally. The result is a new generation of product formulations that enable vaccines, drugs, and nutraceuticals to be delivered into the body faster, with greater potency, efficiency, and accuracy.

The company’s patented Quicksol ™ solubility technology covers all highly solubilized macrocyclic lactones (including the active ingredients ivermectin and selamectin). MVMD’s solubility technology applied to the ivermectin drug is the only form in the world that uses only excipients currently approved by the U.S. Food and Drug Administration (FDA). This makes MVMD a leading candidate for injections and sublingual applications in humans and significantly broader housing and companion animal treatments due to its low viscosity.

For more company information and contact details, visit


Certain statements in this press release may constitute forward-looking information. Forward-looking information is often, but not always, identified by the use of words such as “anticipate”, “plan”, “estimate”, “expect”, “may”, “be”, “intend”, “should”. and similar expressions. Forward-looking information involves known and unknown risks, uncertainties and other factors that could cause actual results or events to differ materially from those anticipated in such forward-looking information.

Actual results of the company could differ materially from those anticipated in this forward-looking information due to regulatory decisions, competitive factors in the industries in which the company operates, prevailing economic conditions, and other factors, many of which are beyond our control Company.

The company makes forward-looking statements including, but not limited to: commencing, performing and completing maintenance trials for its proprietary Ivectosol 1% technology; the results and effects thereof; the commitment as a consultant to Dr. Rondeau and his participation in the studies; and in general the impact of Ivectosol 1% technology on applicable industries and markets.

The company believes that the expectations contained in the forward-looking information are reasonable, but no assurance can be given that these expectations will prove to be correct and no undue reliance should be placed on such forward-looking information. All forward-looking information contained in this press release is the company’s expectations as of the date of this release and is subject to change after that date. The company disclaims any intention or obligation to update or revise any forward-looking information as a result of new information, future events or for any other reason, except as required by applicable securities laws.

SOURCE Mountain Valley MD Holdings Inc.

For more information: Dennis Hancock, President and Chief Executive Officer of Mountain Valley MD Holdings Inc., phone: 647-725-9755, email: [email protected],

similar links